CDK4/6 inhibitors in advanced breast cancer, what is beyond?

  • Amrallah A. Mohammed | Medical Oncology Department, Faculty of Medicine, Zagazig University, Egypt; King Salman Armed Forces Hospital, Tabuk City, Saudi Arabia.
  • Hanaa Rashied El-mabra Hospital, Zagazig, Egypt.
  • Fifi Mostafa Elsayed Clinical Oncology & Nuclear Medicine, Department Faculty of Medicine Suez Canal University, Egypt.


Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.


Download data is not yet available.
Breast cancer, CDK4/6 inhibitors, predictors of response and resistance.
Abstract views: 817

PDF: 442
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Mohammed, A., Rashied, H., & Elsayed, F. M. (2019). CDK4/6 inhibitors in advanced breast cancer, what is beyond?. Oncology Reviews, 13(2).